
News|Articles|May 1, 2002
Cardiac events: Losartan beats beta blocker in patients with diabetes,HTN, & LVH
Therapy starting with the angiotensin receptor blocker (ARB) losartansignificantly reduced the risk of cardiovascular outcomes and new-onsetdiabetes compared with a beta blocker in older high-risk hypertensive patients,said Björn Dahlöf, MD. The improved outcomes with losartan occurredeven after adjusting for small differences in blood pressure reduction betweenthe two study drugs.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5























